Sarcoma Trials at MSK

Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.

Researchers are comparing treatment with doxorubicin chemotherapy and pembrolizumab immunotherapy to doxorubicin alone for advanced sarcoma. The people in this study have undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).

Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).

The purpose of this study is to assess the safety and effectiveness of giving the investigational immunotherapy drug INCMGA00012 in combination with gemcitabine and docetaxel in patients with inoperable or metastatic soft tissue sarcoma. Gemcitabine and docetaxel are standard treatments for this disease; researchers believe that adding INCMGA00012 may make treatment more effective.

This study is assessing the safety and effectiveness of ASTX727 in people who have malignant peripheral nerve sheath tumors (MPNST) with a mutation in a gene complex called PRC2 (EED or SUZ12). ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PRC2 complex genetic mutation and disrupt the cells' ability to survive and grow.

Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.

This study is assessing the safety and effectiveness of the investigational drug trastuzumab deruxtecan (DS-8201A) in adolescents and young adults with osteosarcoma (bone cancer) that is positive for the HER2 protein and has come back after prior treatment. Trastuzumab deruxtecan includes an antibody (trastuzumab) linked to a chemotherapy drug (deruxtecan). Trastuzumab attaches to HER2-positive cancer cells in a targeted way and delivers deruxtecan to kill them. The treatment is given intravenously (by vein).

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.